Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis

Abstract

Introduction

The objective of this analysis was to examine the relationship between genomic variation and health outcomes in studies performed in non-small cell lung cancer (NSCLC) patients treated with single agent epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) using a systematic review with statistical pooling of data.

Methods

We performed a systematic search of the literature using the MEDLINE, BIOSIS, and EMABASE databases from July 1997 to July 2007. Eligible studies were evaluated for quality and clinical, methodological, and statistical heterogeneity. Abstracted data judged to be sufficiently homogenous were pooled using a fixed effect model.

Results

Conclusion

In conclusion, EGFR mutation and protein expression status may provide useful clinical information in terms of the likelihood of tumor response and disease prognosis. EGFR gene copy number and to a lesser extent, EGFR protein expression status, appear to be promising biomarkers for predicting a survival benefit with EGFR-TKI therapy in second line NSCLC, but further evidence is needed.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3

References

  1. American Cancer Society (2007) Cancer facts and figures 2007. American Cancer Society, Atlanta

  2. Argiris A, Hensing T, Yeldandi A, Patel S, Raji A, Sturgis C et al (2006) Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story. J Thorac Oncol 1(1):52–60. doi:10.1097/01243894-200601000-00011

  3. Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW et al (2005) Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23(31):8081–8092. doi:10.1200/JCO.2005.02.7078

  4. Bunn PA Jr, Dziadziuszko R, Varella-Garcia M, Franklin WA, Witta SE, Kelly K et al (2006) Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy. Clin Cancer Res 12(12):3652–3656. doi:10.1158/1078-0432.CCR-06-0261

  5. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L et al (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97(9):643–655

  6. Cappuzzo F, Ligorio C, Janne PA, Toschi L, Rossi E, Trisolini R et al (2007) Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol 25(16):2248–2255. doi:10.1200/JCO.2006.09.4300

  7. Chou TY, Chiu CH, Li LH, Hsiao CY, Tzen CY, Chang KT et al (2005) Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 11(10):3750–3757. doi:10.1158/1078-0432.CCR-04-1981

  8. Cortes-Funes H, Gomez C, Rosell R, Valero P, Garcia-Giron C, Velasco A et al (2005) Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol 16(7):1081–1086. doi:10.1093/annonc/mdi221

  9. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS et al (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23(25):5900–5909. doi:10.1200/JCO.2005.02.857

  10. Eberhard DA, Giaccone G, Johnson BE (2008) Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 26(6):983–994. doi:10.1200/JCO.2007.12.9858

  11. Giaccone G, Gallegos Ruiz M, Le Chevalier T, Thatcher N, Smit E, Rodriguez JA et al (2006) Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 12(20 Pt 1):6049–6055. doi:10.1158/1078-0432.CCR-06-0260

  12. Greenland S (1987) Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 9:1–30

  13. Haas-Kogan DA, Prados MD, Lamborn KR, Tihan T, Berger MS, Stokoe D (2005) Biomarkers to predict response to epidermal growth factor receptor inhibitors. Cell Cycle 4(10):1369–1372

  14. Han SW, Hwang PG, Chung DH, Kim DW, Im SA, Kim YT et al (2005) Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer 113(1):109–115. doi:10.1002/ijc.20550

  15. Han SW, Kim TY, Jeon YK, Hwang PG, Im SA, Lee KH et al (2006a) Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res 12(8):2538–2544. doi:10.1158/1078-0432.CCR-05-2845

  16. Han SW, Kim TY, Lee KH, Hwang PG, Jeon YK, Oh DY et al (2006b) Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. Lung Cancer 54(2):201–207. doi:10.1016/j.lungcan.2006.07.007

  17. Hirsch FR, Witta S (2005) Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer. Curr Opin Oncol 17(2):118–122. doi:10.1097/01.cco.0000155059.39733.9d

  18. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Franklin WA, Dziadziuszko R, Thatcher N et al (2006) Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24(31):5034–5042. doi:10.1200/JCO.2006.06.3958

  19. Hirsch FR, Varella-Garcia M, Cappuzzo F, McCoy J, Bemis L, Xavier AC et al (2007) Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 18(4):752–760. doi:10.1093/annonc/mdm003

  20. Hsieh MH, Fang YF, Chang WC, Kuo HP, Lin SY, Liu HP et al (2006) Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer. Lung Cancer 53(3):311–322. doi:10.1016/j.lungcan.2006.06.005

  21. Ichihara S, Toyooka S, Fujiwara Y, Hotta K, Shigematsu H, Tokumo M et al (2007) The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int J Cancer 120(6):1239–1247. doi:10.1002/ijc.22513

  22. Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J et al (2007) Phase II clinical trial of chemotherapy-naive patients > or =70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 25(7):760–766. doi:10.1200/JCO.2006.07.5754

  23. Johnson BE, Janne PA (2005) Selecting patients for epidermal growth factor receptor inhibitor treatment: a FISH story or a tale of mutations? J Clin Oncol 23(28):6813–6816. doi:10.1200/JCO.2005.97.008

  24. Kelley MJ, McCrory D (2005) Report on the relative efficacy of oral cancer therapy for medicare beneficiaries versus currently covered therapy: part 1, gefitinib and erlotinib for non-small cell lung cancer. Agency for Healthcare Research and Quality, Rockville

  25. Kim KS, Jeong JY, Kim YC, Na KJ, Kim YH, Ahn SJ et al (2005) Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res 11(6):2244–2251. doi:10.1158/1078-0432.CCR-04-2081

  26. Kondo M, Yokoyama T, Fukui T, Yoshioka H, Yokoi K, Nagasaka T et al (2005) Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery. Lung Cancer 50(3):385–391. doi:10.1016/j.lungcan.2005.06.008

  27. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129–2139. doi:10.1056/NEJMoa040938

  28. Mitsudomi T, Kosaka T, Endoh H (2005) Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small cell lung cancer with postoperative recurrence. J Clin Oncol 23(11):2513–2520. doi:10.1200/JCO.2005.00.992

  29. Mu XL, Li LY, Zhang XT, Wang MZ, Feng RE, Cui QC et al (2005) Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer. Clin Cancer Res 11(12):4289–4294. doi:10.1158/1078-0432.CCR-04-2506

  30. NCCN (2006) NCCN clinical practice guidelines in oncology: non-small cell lung cancer V.2.2006. NCCN, Fort Washington

  31. NICE (2006) ERG report: erlotinib for the treatment of relapsed non-small cell lung cancer. The National Institute for Health and Clinical Excellence, Liverpool

  32. Niho S, Kubota K, Goto K, Yoh K, Ohmatsu H, Kakinuma R et al (2006) First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 24(1):64–69. doi:10.1200/JCO.2005.02.5825

  33. Oshita F, Matsukuma S, Yoshihara M, Sakuma Y, Ohgane N, Kameda Y et al (2006) Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer. Br J Cancer 95(8):1070–1075. doi:10.1038/sj.bjc.6603396

  34. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497–1500. doi:10.1126/science.1099314

  35. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I et al (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101(36):13306–13311. doi:10.1073/pnas.0405220101

  36. Parra HS, Cavina R, Latteri F, Zucali PA, Campagnoli E, Morenghi E et al (2004) Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer. Br J Cancer 91(2):208–212

  37. Pettiti D (2000) Meta-analysis, decision Analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine, 2nd edn. Oxford University Press, New York

  38. Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES et al (2006) Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12(3 Pt 1):839–844. doi:10.1158/1078-0432.CCR-05-1846

  39. Rosell R, Ichinose Y, Taron M, Sarries C, Queralt C, Mendez P et al (2005) Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. Lung Cancer 50(1):25–33. doi:10.1016/j.lungcan.2005.05.017

  40. Satouchi M, Negoro S, Funada Y, Urata Y, Shimada T, Yoshimura S et al (2007) Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib. Br J Cancer 96(8):1191–1196. doi:10.1038/sj.bjc.6603710

  41. Sequist LV, Joshi VA, Janne PA, Muzikansky A, Fidias P, Meyerson M et al (2007) Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist 12(1):90–98. doi:10.1634/theoncologist.12-1-90

  42. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353(2):123–132. doi:10.1056/NEJMoa050753

  43. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II et al (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97(5):339–346

  44. Shih JY, Gow CH, Yu CJ, Yang CH, Chang YL, Tsai MF et al (2006) Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer 118(4):963–969. doi:10.1002/ijc.21458

  45. Sone T, Kasahara K, Kimura H, Nishio K, Mizuguchi M, Nakatsumi Y et al (2007) Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer. Cancer 109(9):1836–1844. doi:10.1002/cncr.22593

  46. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U et al (2005) Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23(28):6829–6837. doi:10.1200/JCO.2005.01.0793

  47. Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L et al (2005) Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 11(16):5878–5885. doi:10.1158/1078-0432.CCR-04-2618

  48. Tokumo M, Toyooka S, Kiura K, Shigematsu H, Tomii K, Aoe M et al (2005) The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 11(3):1167–1173

  49. Tomizawa Y, Iijima H, Sunaga N, Sato K, Takise A, Otani Y et al (2005) Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res 11(19 Pt 1):6816–6822. doi:10.1158/1078-0432.CCR-05-0441

  50. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J et al (2005) Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med 353(2):133–144. doi:10.1056/NEJMoa050736

  51. Uramoto H, Mitsudomi T (2007) Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br J Cancer 96(6):857–863. doi:10.1038/sj.bjc.6603665

  52. Uramoto H, Sugio K, Oyama T, Ono K, Sugaya M, Yoshimatsu T et al (2006) Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese. Lung Cancer 51(1):71–77. doi:10.1016/j.lungcan.2005.08.006

  53. Varella-Garcia M (2006) Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay. Diagn Pathol 1:19. doi:10.1186/1746-1596-1-19

  54. Wu YL, Zhong WZ, Li LY, Zhang XT, Zhang L, Zhou CC et al (2007) Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol 2(5):430–439. doi:10.1097/01.JTO.0000268677.87496.4c

  55. Yang CH, Shih JY, Chen KC, Yu CJ, Yang TY, Lin CP et al (2006) Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer. Cancer 107(8):1873–1882. doi:10.1002/cncr.22220

  56. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2):127–137. doi:10.1038/35052073

Download references

Acknowledgment

Josh Carlson was supported in part by a Pre Doctoral Fellowship in Health Outcomes from the PhRMA Foundation.

Conflict of interest statement

The authors would like to disclose the following financial relationships: Josh Carlson has served as a consultant to Genentech, Inc. David Veenstra has received research funding and served as a consultant to Genentech, Inc., F. Hoffmann-La Roche, and Bristol-Myers Squibb. Scott Ramsey has served as a consultant to Genentech, Inc. and has received research funding from Bristol-Myers Squibb. Lou Garrison has been a consultant to Genentech, Inc. and F. Hoffmann-La Roche, Ltd.

Author information

Correspondence to Josh John Carlson.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Carlson, J.J., Garrison, L.P., Ramsey, S.D. et al. Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis. J Cancer Res Clin Oncol 135, 1483–1493 (2009). https://doi.org/10.1007/s00432-009-0595-3

Download citation

Keywords

  • Non-small cell
  • EGFR
  • Erlotinib
  • Gefitinib
  • Response
  • Survival